AMGEN Inc

NASDAQ: AMGN
$307.81
+$18.79 (+6.5%)
Closing Price on February 5, 2025

AMGN Articles

The short interest data are out for the April 29 settlement date, and short interest moves were mixed in these selected biotech stocks.
One time when missing earnings estimates doesn't matter much is when there is bidding war for the company. That's the position that Medivation found itself in.
With earnings having just been released for some of the top biotech companies, we saw a flurry of analyst calls by the week's end.
The April 15 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
The March 31 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Regeneron Pharmaceuticals saw its shares halted on Wednesday afternoon after a jury ruled in favor of Amgen on a cholesterol drug patent.
The February 29 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Citigroup came out with a biotech upgrade of sorts on Thursday. The firm issued brand new Buy ratings on four of the largest names within the biotech space.
The February 12 short interest data have been compared with the previous report, and short interest increased across the board in these selected biotech stocks.
The January 29 short interest data have been compared with the previous report, and short interest was mixed in most of the selected biotech stocks.
A recent Jefferies research note indicates that the multiples for the four largest biotechs have dipped below that of the S&P for the first time since early in 2011, despite displaying higher...
Amgen reported better-than-expected fourth-quarter financial results after the markets closed Thursday.
Short interest increased in most of these selected biotech stocks for the most recent settlement date.
Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. It initiated several top biotech stocks with an Outperform rating.
The short interest data are out for the December 31 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.